Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.60 |
| ▸ | AOC2 | O75106 | 6/20 | 0.60 |
| ▸ | MAOA | P21397 | 6/20 | 0.60 |
| ▸ | DAO | P14920 | 2/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505391 | 0.88 | AOC2 (0.68) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1282141 | 0.76 | AOC2 (0.64) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL1282142 | 0.76 | AOC2 (0.64) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL3505054 | 0.76 | TDP1 (0.54) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL10615833 | 0.76 | TDP1 (0.54) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL10615963 | 0.76 | TDP1 (0.54) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL3505446 | 0.75 | MAOB (0.62) | MAOBAOC2MAOADAOAOC3 | |
| SCHEMBL9195201 | 0.72 | HTT (0.53) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL6203335 | 0.72 | HTT (0.53) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL9194779 | 0.72 | WDR5 (0.51) | TP53CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885AOC2 146/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.